Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Functional cardiomyocytes can now be derived routinely from hPSCs (human pluripotent stem cells), which collectively include embryonic and induced pluripotent stem cells. This technology presents new opportunities to develop pharmacologically relevant in vitro screens to detect cardiotoxicity, with a view to improving patient safety while reducing the economic burden to industry arising from high drug attrition rates. In the present article, we consider the need for human cardiomyocytes in drug-screening campaigns and review the strategies used to differentiate hPSCs towards the cardiac lineage. During early stages of differentiation, hPSC-cardiomyocytes display gene expression profiles, ultra-structures, ion channel functionality and pharmacological responses reminiscent of an embryonic phenotype, but maturation during extended time in culture has been demonstrated convincingly. Notably, hPSC-cardiomyocytes have been shown to respond in a highly predictable manner to over 40 compounds that have a known pharmacological effect on the human heart. This suggests that further development and validation of the hPSC-cardiomyocyte model as a tool for assessing cardiotoxicity is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
Xue, T., Cho, H. C., Akar, F. G., Tsang, S.-Y., Jones, S. P., Marbán, E., Tomaselli, G. F., & Li, R. A. (2005) · Circulation · doi:10.1161/01.cir.0000151313.18547.a2 · Cited by 480
Liu, J., Lieu, D. K., Siu, C. W., Fu, J.-D., Tse, H.-F., & Li, R. A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00060.2009 · Cited by 109
The human embryonic stem cell-derived cardiomyocyte as a pharmacological model
Harding, S. E., Ali, N. N., Brito-Martins, M., & Gorelik, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.008 · Cited by 84
Brito‐Martins, M., Harding, S. E., & Ali, N. N. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707619 · Cited by 74
Cited by
NKX2-5eGFP/w hESCs for isolation of human cardiac progenitors and cardiomyocytes
Elliott, D. A., Braam, S. R., Koutsis, K., Ng, E. S., Jenny, R., Lagerqvist, E. L., Biben, C., Hatzistavrou, T., Hirst, C. E., Yu, Q. C., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1740 · Cited by 426
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407
Watkins, S. J., Borthwick, G. M., & Arthur, H. M. (2011) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-010-9368-1 · Cited by 397
Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes
Robertson, C., Tran, D. D., & George, S. C. (2013) · Stem Cells · doi:10.1002/stem.1331 · Cited by 354
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159
“…are clinically important cells types for drug toxicity studies, methods to direct the differentiation of human pluripotent stem cells along these lineages could be of tremendous value in predicting serious adverse effects leading to drug attrition and safety concerns (Dick et al., 2010).”
Metadata
- Authors
- Dick, E., Rajamohan, D., Ronksley, J., & Denning, C.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2010-07-26
- Volume
- 38
- Issue
- 4
- Pages
- 1037-1045
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W1979904726
- Cited by
- 110
- References
- 6
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. https://app.cochat.ai/papers/10.1042/bst0381037
- The paper
- Dick, E., Rajamohan, D., Ronksley, J., & Denning, C. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochemical Society Transactions. https://doi.org/10.1042/bst0381037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.